The global gabapentin drug market is anticipated to grow at a CAGR of 3.4% during the forecast period. The rising prevalence of epilepsy disease has created a demand for the development of new drugs for its treatment which in turn drives the global gabapentin drugs market growth. The market growth is driven by the strong focus of pharmaceutical companies and research organizations on the R&D of drugs for gabapentin, creating an increased incidence of seizures. For instance, in 2019, the drug company Lupine had launched its standard Clobazam tablets in the US to treat a patient suffering from epilepsy since childhood and the company introduced Clobazam tablets in doses of 10 mg and 20 mg, after receiving approval from the USFDA. 

Gabapentin is an anti-convulsants, a type of medication that helps control seizures in people with epilepsy disorder. Another type of gabapentin is used to treat chronic leg pain or certain types of nerve pain and the mechanism of action of gabapentin is to alter electrical impulses in the brain and trigger neurotransmitters, that send signals between nerve cells. In addition, leading pharmaceutical companies are focusing on the development of drugs for epilepsy disorder treatment.

However, a lack of medical reimbursement policies in developing nations is rising the costs of treatments, where adverse effects associated with tight regulatory policies are expected to hamper the market growth. In addition, lack of technology, increased productivity (antibiotics) recalls, use of alternative drugs, and constraints in supply chain management in drug transport are challenging the growth of the market. This report will further analyze all the primary and secondary factors that are directly or indirectly influencing the growth of the gabapentin drug market during the forecast period.

Diagnosis and treatment of several patients with different disorders were postponed during the COVID-19 crisis as hospital beds were reserved for COVID-19 patients. Due to this reason the market players had reported a significant decline in their revenue during the COVID-19 pandemic. However, as the situation got normalized the market had bounced back to its pre-COVID-19 pandemic level.

Segmental Outlook 

The global gabapentin drug market is segmented based on type and application. Based on the type, the market is segmented into capsule, tablet, and oral solution. Among these types, the oral solution segment is expected to grow fastest during the forecast period as it disperses rapidly in the body after consumption.

Based on the application, the market is sub-segmented into epilepsy, neuropathic pain, and restless legs syndrome. A new AED with additional approved indications for restless leg syndrome and neuropathic pain may have an increased market size that is three times larger than just epilepsy. Since gabapentin is an effective AED, its growth has been excellent in the treatment of epilepsy, bipolar disorder, and neuropathic pain. These segments can further be customized as per the requested research requirements.

Regional Outlooks

The global gabapentin drug market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, and Others), and the Rest of the World (the Middle East & Africa, and Latin America).  The market can also be analyzed for a particular region or country level as per the requirement. 

Global Gabapentin Drug Market Growth by Region, 2022-2028

The North American Region Holds the Major Share in the Global Gabapentin Drug Market

The North American region holds the major share in the global gabapentin drug market due to significantly high healthcare spending. The US and Canada are the major contributing nation in this regional market. The US spends almost 17.7% of GDP on healthcare expenditure, whereas Canada spends 15.2% of GDP on healthcare as per Organization for Economic Co-operation and Development (OECD, 2019). The rising prevalence of epilepsy is another factor driving the growth of the market in this region. According to the CDC, 1.2% of the US population (3.4 million people) had active epilepsy in 2015, out of which 3 million were adults and 470 thousand were children.

Market Players Outlook

The major companies serving the global gabapentin drug market include Merck & Co., Inc., GlaxoSmithKline plc, Sanofi SA, Pfizer Inc., Glenmark Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., and Cipla Inc. Ltd., among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in June 2019, GlaxoSmithKline plc announced the launch of a dispersed Lamictal tablet (lamotrigine dispersible tablet) for the treatment of epilepsy in the Chinese market.

The Report Covers

• Market value data analysis of 2021 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global gabapentin drug market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.